BRITISH pharmaceuticals group
AstraZeneca (AZ) announced last
week that it had agreed to buy a
55% share of Dutch and US based
Acerta Pharma, which is developing
an oncology therapy according to a
report in Yahoo! News.
AZ will pay $2.5b upfront, then
a further $1.5b once Acerta’s
experimental drug acalabrutinib
wins regulatory approval from US
authorities or else by the end of
2018.
Acalabrutinib has reportedly
demonstrated some activity
in treating leukemia and autoimmune
diseases such as lupus
while other research in the
company’s portfolio extends to
other cancers, respiratory diseases
and diabetes therapies.
With shareholders’ blessing,
AZ has the option of buying the
remaining 45% of Acerta for around
$3b conditional upon the drug
gaining regulatory approval the
report said.The above article was sent to subscribers in Pharmacy Daily's issue from 21 Dec 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Dec 15
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.